FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 186 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Brentuximab Approved for Initial Treatment of Advanced Hodgkin Lymphoma April 17, 2018 How NatWest Group are making a difference this Giving Tuesday November 29, 2022 Adjuvant Treatment with Nivolumab Plus Ipilimumab Combination Fails to Improve DFS... February 22, 2023 Breast Cancer Centers Rarely Follow National Screening Recommendations, Study Says March 19, 2021 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Lazertinib A Large Case-Control Study of Hodgkin Lymphoma Survivors Suggests a Dose-Response... Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer ESMO Breast Cancer Congress 2023
